Atty: Docket No.: PB60390USw

Amendments to the Claims:

1. (Original) A compound of formula (f):

wherein

X represents 0 or S;

 R_1 represents $C_{1:6}$ alkyl, $C_{2:6}$ cycloalkyl, $C_{3:6}$ cycloalkylmathyl or $C_{3:6}$ cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or R_1 represents aryl, substituted aryl, heteroaryl or substituted heteroaryl;

 R_z represents hydrogen, methyl, which may be in either the α or β configuration, or methylene;

 $R_{\rm s}$ and $R_{\rm s}$ are the same or different and each independently represents hydrogen, halogen or a methyl group;

and represents a single or a double bond; or a physiologically acceptable salt or solvate thereof.

- (Original) A compound as claimed in claim 1 wherein X represents O.
- 3. (Previously presented) A compound as claimed in claim 1 wherein R_1 represents a $C_{3,6}$ cyclosikyl group optionally substituted by one or more methyl or chlorine groups.
- 4. (Previously presented) A compound as claimed in claim 1 wherein R₁ represents 2,2,3,3-tetramethylcyclopropyt.

Atty. Docket No.: P860390USw

- 5. (Previously presented) A compound as claimed in claim 1 wherein R_2 represents methyl in the α -configuration.
- 6. (Previously presented) A compound as claimed in claim 1 wherein R_2 and R_4 are both fluorine.
- 7. (Previously presented) A compound as claimed in claim 1 wherein represents a double bond.
- 8. (Currently Amended) A compound as claimed in claim 1 which is

 6α , 9α -Difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 β -carbothloic acid Scyanomethyl ester;

17α-(4-[(Diethylamino)sulphonyl]benzoyl)oxy-6α,9α-diffuoro-11β-hydroxy-16α-methyl-3oxo-androsta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester;

17α-(5-Chicro-4-methoxy-thiophene-3-carbonyl)σxy-6α,9α-difluoro-11β-hydroxy-16α-methyl -3-oxo-androsta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester:

 6α , 9α -Diffuoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 β -carboxylic acid cyanomethylester;

17α-(Cyclohexylcarbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

6α,9α-Diffuoro-17α-(2,6-diffuorobenzoyl)oxy-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

Atty, Docket No.: P860390USw

6α,9α-Diffuoro-11β-hydroxy-17α-(4-methoxybenzoyl)oxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

17 α -(4-Cyanobenzoyi)oxy-6 α ,9 α -diffuoro-11 β -hydroxy-18 α -methyl-3-oxo-androsta-1,4-diene-17 β -carboxyfic acid cyanomethyl ester;

17α-(Cyclopentylmethylcarbonyl)oxy-6α,9α-diffuoro-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carboxylic acid cyanomethyl ester:

6α,9α-Diffuoro-17α-(3,3-dimethy/butanoy/)oxy-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

6α,9α-Difluoro-11β-hydroxy-17α-(2-isopropyl-1,3-thiazole-4-carbonyl)oxy-16α-methyl-3oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

6α,9α-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(quinoline-2-carbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

6α,9α-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(5-trifluoromethyl-furan-2-carbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester:

6α,9α-Difluoro-11β-hydroxy-16α-methyl -17α-(5-methylsulphonyl-thiophene-2-carbonyl)oxy-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

6α,θα-Difluoro-11β-hydroxy-16α-methyl -17α-(5-methylthio-thjophene-2-carbonyl)oxy-3oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester:

6α,9α-Diffuoro-17α-(5-ethyl-isoxazole-3-carbonyl)oxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carboxylic acid cyanomethyl ester: Atty, Docket No.: PB60390USw

9α-Fluoro-11β-hydroxy-16β-methyl-3-oxo-17α-(2,2,3,3tetramethylcyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester--;

 6α , 9α -Diffuoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androst-4-ene-17 β -carboxylic acid cyanomethylester;

17α-(5-Chloro-4-methoxy-thiophene-3-carbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl -3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

 17α -(2,2-Dichloro-3,3-dimethylciopropylcarbonyl)oxy- 6α , 9α -difluoro-11 β -hydroxy- 16α -methyl-3-oxo-androsta-1,4-diene-17 β -carboxylic acid cyanomethyl ester;

17α-(2,2-Dichloro-3,3-dimethylclopropylcarbonyl)oxy-8α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothiolc acid S-cyanomethyl ester;

17α-(Cyclohexylcarbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester;

6α,9α-Diffuoro-11β-hydroxy-16α-methyl -17α-(5-methylsulphonyl-thiophene-2carbonyl)oxy-3-oxo-androsta-1,4-diene-17β-carbothioic acid S- cyanomethyl ester;

δα,9α-Diffuoro-11β-hydroxy-16α-methyl-3-oxo-17α-(5-trifluoromethyl-furan-2-carbonyl)oxy-androsta-1,4-diene-17β-carbothicic acid S-cyanomethyl ester; or

6α,9α-Difluoro-17α-(3-(difluoromethylthio)benzoyl)oxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester.

Original) A compound as claimed in claim 8 which is

Atty, Docket No.: PB60390USw

 6α , 9α -Diffuoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17 β -carbothioic acid Scyanomethyl ester;

6α,9α-Diffuoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

9α-Fluoro-11β-hydroxy-16β-methyl-3-oxo-17α-(2,2,3,3-tetramethylcyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethylester:

17α-(Cyclohexylcarbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

17α-(Cyclopentylmethylcarbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

6α.9α-Diffuoro-17α-(3,3-dimethylbutanoyl)oxy-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

6α,9α-Diffuoro-17α-(3-(diffuoromethylthio)benzoyl)oxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester:

17α-(Cyclohexylcarbonyl)oxy-6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-cyanomethyl ester:

6α,9α-Diffuoro-17α-(6-ethyl-isoxazole-3-carbonyl)oxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carboxylic acid cyanomethyl ester;

6α,9α-Diffuoro-11β-hydroxy-16α-methyl -17α-(5-methylthio-thiophene-2-carbonyl)oxy-3oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester: Alty, Docket No.: PB60390USw

6α,9α-Diffuoro-11β-hydroxy-17α-(2-isopropyl-1,3-thiazole-4-carbonyl)oxy-16α-methyl-3oxo-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester:

 17α -(2,2-Dichloro-3,3-dimethylciopropylcarbonyl)oxy- 6α , 9α -diffuoro- 11β -hydroxy- 16α -methyl-3-oxo-androsta-1,4-diene- 17β -carbothioic acid S-cyanomethyl ester; or

 17α -(2,2-Dichloro-3,3-dimethylclopropylcarbonyl)oxy- 6α , 9α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-androsta-1,4-diene-17 β -carboxylic acid cyanomethyl ester.

10. (Original) A compound as claimed in claim 9 which is

17 α -(2,2-Dichloro-3,3-dimethylciopropylcarbonyl)oxy-6 α ,9 α -diffuoro-11 β -hydroxy-16 α -methyl-3-oxo-androsta-1,4-diene-17 β -carboxylic acid cyanomethyl ester;

6α,9α-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carbothioic acid Scyanomethyl ester; or

6α,9α-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethylester

Original) A compound as claimed in claim 10 which is

δα,θα-Difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3tetramethycyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester.

12. (Previously presented) A compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof for use in veterinary or human medicine.

Atty, Docket No.: PB60390USw

- 13. (Previously presented) Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof for the manufacture of a medicament for the treatment of inflammatory and/or allergic conditions.
- 14. (Previously presented) A pharmaceutical composition comprising a compound of formula (i) as defined in claim 1 or a physiologically acceptable solvate thereof together, if desirable, in admixture with one or more physiologically acceptable diluents or carriers.
- 15. (Previously presented) A pharmaceutical aerosol formulation comprising a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof, and a fluorocarbon or hydrogen-containing chiorofluoro carbon as propellant, optionally in combination with a surfactant and/or a cosolvent.
- (Original) A pharmaceutical composition according to claim 15, which further comprises another therapeutically active agent.
- 17. (Original) A pharmaceutical composition according to claim 16 in which said another therapeutically active agent is a 0,-adrenoreceptor agonist.
- 18. (Previously presented) A method for the treatment of a human or animal subject with an anti-inflammatory and/or allergic condition, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable solvate thereof.

19-20. (Cancelled)

(Previously presented) A process for preparing a compound of formula (II)

where R₁ represents 2,2,3,3 – tetramethyl cyclopropyl and R₂, R₃, R₄, X and are as defined in claim 1 which process comprises reaction of the 1,2-dimethyl-1/4-imidazolium ester of 2,2,3,3-tetramethylcyclopropane carboxylic acid (IV)

with the corresponding 17a-hydroxyl derivative of formula (III)

22. (Original) A process as claimed in claim 21 in which X represents O.